Primary contact physiotherapy versus standard emergency physician care in the emergency department: a Time-Driven Activity-Based Costing analysis
Abstract
Objectives: Compare the average cost of an emergency department (ED) visit between three ED care models, namely emergency physician-led management (usual care), management by a primary contact physiotherapist and an emergency physician (intervention), and physiotherapist-led management (sensitivity analysis).
Methods: Cost study (Canadian Public Payer perspective) based on data collected during a pragmatic randomized clinical trial (2018-2019) conducted in an urban Canadian academic ED (CHUL, Quebec City, Canada; n = 78, 18-80 years old). Costs incurred for the management of persons presenting to the ED for a minor musculoskeletal disorder were calculated using Time-Driven Activity-Based Costing, in which time invested with a patient determines care costs. The main outcome measure was the average cost of an ED visit. Generalized linear models with Gamma distributions and log links were used to assess whether there were significant differences in average costs between the care models.
Results: Mean ED visit cost was $267.08 (2019 $CAD, 95% CI 212.75 to 346.40) for physiotherapist and emergency physician management, compared with $245.14 for emergency physician-led management (169.46 to 336.72), resulting in a non-significant absolute difference of 21.94 CAD/patient (- 87.33 to 132.63) between models. Sensitivity analyses showed that the average cost of physiotherapist-led ED management could be $194.38 (161.50 to 234.34), representing an average saving of 50.76 CAD/patient…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 78 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.